Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Songwen Zhou"'
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background m6A modification has close connection with the occurrence, development, and prognosis of tumors. This study aimed to explore the roles of m6A modification and its related mechanisms in non-small cell lung cancer (NSCLC). Methods N
Externí odkaz:
https://doaj.org/article/032f5b0c05514282bba0284cc8a99378
Autor:
Qiyu Fang, Xiaoying Wan, Angelica D’Aiello, Hui Sun, Weiquing Gu, Yixue Li, Caicun Zhou, Boxiong Xie, Qinfang Deng, Haiying Cheng, Songwen Zhou
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionDespite the benefit of adjuvant systemic therapy for patients with resected non-small cell lung cancer (NSCLC), the risk of postoperative recurrence remains high. Our objective was to characterize temporal genetic heterogeneity between pr
Externí odkaz:
https://doaj.org/article/8be4a8ac5b7b4ac0a6308f3dec7b3e97
Publikováno v:
Cancer Cell International, Vol 22, Iss 1, Pp 1-16 (2022)
Abstract Background Osimertinib resistance limits the treatment of epidermal growth factor receptor-(EGFR)-mutated non-small-cell lung carcinoma (NSCLC). The mechanisms of osimertinib resistance need to be elucidated to determine alternative treatmen
Externí odkaz:
https://doaj.org/article/74d1b845fe304f2095704b297d7a04f2
Publikováno v:
BMC Bioinformatics, Vol 21, Iss 1, Pp 1-13 (2020)
Abstract Background Hybrid capture-based next-generation sequencing of DNA has been widely applied in the detection of circulating tumor DNA (ctDNA). Various methods have been proposed for ctDNA detection, but low-allelic-fraction (AF) variants are s
Externí odkaz:
https://doaj.org/article/9109c4be1bb3421c87d1ed3a4b4c1449
Autor:
Qinfang Deng, Qiyu Fang, Hui Sun, Aditi P. Singh, Mariam Alexander, Shenduo Li, Haiying Cheng, Songwen Zhou
Publikováno v:
Cancer Medicine, Vol 9, Iss 6, Pp 2085-2095 (2020)
Abstract Introduction Next‐generation sequencing (NGS) and digital polymerase chain reaction (PCR) based platforms have been used to detect EGFR mutations in plasma circulating tumor DNA (ctDNA) with high accuracy. Generally, molecular testing is p
Externí odkaz:
https://doaj.org/article/3a0929f4e1df49519af6639000b08d20
Publikováno v:
Chinese Journal of Lung Cancer, Vol 19, Iss 12, Pp 864-870 (2016)
Background and objective Non-small cell lung cancer (NSCLC) presents the highest morbidity and mortality among malignant tumors worldwide. The overall effective rate of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is 30% to 4
Externí odkaz:
https://doaj.org/article/218bbbe5f713402c9d57b413ced36b01
Autor:
Qinfang Deng, Boxiong Xie, Leilei Wu, Xianxiu Ji, Chao Li, Li Feng, Qiyu Fang, Yuchen Bao, Jialu Li, Shengnan Jin, Chunming Ding, Yixue Li, Songwen Zhou
Publikováno v:
Heliyon, Vol 4, Iss 12, Pp e01031- (2018)
Purpose: Although many studies have reported on the resistance mechanism of first-generation EGFR TKIs (1st EGFR TKIs) treatment, large-scale dynamic ctDNA mutation analysis based on liquid biopsy for non-small cell lung cancer (NSCLC) in the Chinese
Externí odkaz:
https://doaj.org/article/8bd9179608044c05a0b014eb374240cc
Publikováno v:
Chinese Journal of Lung Cancer, Vol 11, Iss 2, Pp 251-255 (2008)
Background and Objective It has been proven that ERCC1 (excision repair cross-complementation group 1) plays an important role in tumor sensitivity to platinum-based chemotherapy. This study was to examine the relationship between ERCC1 expression in
Externí odkaz:
https://doaj.org/article/35bc33da5121440d9624b453bccb44a1
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0129663 (2015)
Src and the mammalian target of rapamycin (mTOR) signaling are commonly activated in non-small cell lung cancer (NSCLC) and hence potential targets for chemotherapy. Although the combined use of Src inhibitor Dasatinib with other chemotherapeutic age
Externí odkaz:
https://doaj.org/article/f4007f07ec474d0aade9ca2eea1e9ddb
Autor:
Aditi P. Singh, Songwen Zhou, Mariam Alexander, Shenduo Li, Hui Sun, Qiyu Fang, Haiying Cheng, Qinfang Deng
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 6, Pp 2085-2095 (2020)
Cancer Medicine, Vol 9, Iss 6, Pp 2085-2095 (2020)
Introduction Next‐generation sequencing (NGS) and digital polymerase chain reaction (PCR) based platforms have been used to detect EGFR mutations in plasma circulating tumor DNA (ctDNA) with high accuracy. Generally, molecular testing is performed